<DOC>
	<DOCNO>NCT00580320</DOCNO>
	<brief_summary>Bortezomib enhance activity dacarbazine melanoma soft tissue sarcoma . Weekly administration combination prove feasible tolerable appropriate dose .</brief_summary>
	<brief_title>Safety Study Dacarbazine Bortezomib Melanoma Soft Tissue Sarcoma</brief_title>
	<detailed_description>The primary objective determine recommend phase II dose combination dacarbazine bortezomib administer weekly . Secondary objective determine maximum tolerate dose combination observe anti-tumor activity term response rate ( ) , duration response , time progression , time treatment ( measure antitumor activity treatment tolerance ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Parathyroid Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologic diagnosis cutaneous mucosal melanoma , soft tissue sarcoma ( STS ) , APUD ( amine precursor uptake decarboxylation ) tumor . APUD tumor include parathyroid carcinoma , medullary carcinoma thyroid , small cell carcinoma lung , pheochromocytoma , islet cell tumor , carcinoid tumor , malignant paraganglioma . Measurable evaluable disease appropriate resection and/or radiation curative intent . Patients small cell carcinoma must extend stage disease , limited stage disease , must receive least one prior systemic therapy . Age 18 year great ECOG Performance Status 0 1 Women must postmenopausal , infertile result surgical procedure , willing use medically accept form birth control ( abstinence , hormonal contraceptive , intrauterine device , diaphragm spermicide , condon spermicide ) duration study treatment . Men also must agree use medically accept form birth control duration study treatment . Uncontrolled brain metastatic disease Platelet count &lt; 100 Absolute neutrophil count &lt; 1.5 Blood transfusion hematopoietic growth factor cytopenia within one month enrollment . Calculated measure ( Cockcroft Gault formula ) creatinine clearance &lt; 30 mL/minute AST &gt; 3 time upper limit normal , unless elevation due metastatic disease , case AST &gt; 5 time upper limit normal Bilirubin &gt; 2 mg/mL Grade 2 great peripheral neuropathy Hypersensitivity bortezomib , boron , mannitol , dacarbazine Pregnant nursing Other investigational drug within 14 day enrollment Other medical condition ( ) opinion investigator/subinvestigator might compromise objective study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>APUD tumor</keyword>
	<keyword>dacarbazine</keyword>
	<keyword>bortezomib</keyword>
	<keyword>velcade</keyword>
</DOC>